Low-Dose Combination Formulation for Premature Ejaculation Delay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for premature ejaculation often require higher doses of drugs, leading to intolerable side effects, and there is a need for a method and formulation that provides superior ejaculation delay with reduced side effects.
Innovation Solution
A low dose combination therapy using Tadalafil, Silodosin, and Paroxetine in a single pill formulation, administered in specific dosages to achieve extended intra-vaginal ejaculatory latency time (IELT) while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of drugs are used to achieve delay in ejaculation, then the effectiveness of treatment is improved, but side effects become intolerable
Solution Approach 1:
The patent divides the treatment into multiple drug components (PDE5i, alpha-1a antagonist, and SSRI) administered in low doses simultaneously. This segmentation allows each drug to contribute to the overall therapeutic effect without requiring high doses of any single agent, thereby reducing side effects while maintaining treatment effectiveness.
Solution Approach 2:
The patent combines three different drug classes (PDE5i, alpha-1a antagonist, and SSRI) into a single combination therapy. This merging creates synergistic effects where the drugs work together to delay ejaculation more effectively than any single drug could alone, allowing for lower individual doses and reduced side effects.
2Ease of operation
If single drug therapy is used, then treatment simplicity is maintained, but side effects increase and effectiveness is limited
Solution Approach 1:
The patent merges multiple drug classes into a single combination formulation that can be administered as one treatment regimen. This maintains ease of operation by providing a unified treatment approach while reducing side effects through the synergistic low-dose mechanism of the combined drugs.
Data Source
AI summary
A method of treating premature ejaculation in men may include administering a therapeutically effective dosage of a formulation to a patient in need thereof. The formulation for treating male premature ejaculation may include a phosphodiesterase 5 inhibitor (PDE5i), such as Tadalafil; an alpha-1 adrenoreceptor (alpha-1a) selective antagonist, such as Silodosin; and a selective serotonin reuptake inhibitor (SSRI), such as Paroxetine.